Symple Surgical, Inc. Retains Objective Capital Partners to Explore Strategic and Financial Partnerships

Posted April 17, 2018 by OCP | Post a Comment

San Diego, CA and Flagstaff, AZ, April 12, 2018: — Symple Surgical, Inc., a privately-held, early-stage medical device company focused on developing novel therapeutic technologies using microwave technology for treatment of life-threatening chronic conditions, is pleased to the announce that they have retained Objective Capital Partners as their exclusive financial advisor. Objective Capital Partners, a middle-market Investment Banking firm located in Southern California and focused on mergers & acquisitions (M&A), strategic advisory, capital financing and valuation services, will seek to identify strategic partnerships and financial investors for the Company to progress their lead product Grizzly™ targeting pre-cancerous cells in the elimination of Barrett's Esophagus and Esophageal Adenocarcinoma, the fastest growing cancer worldwide.

Barrett’s Esophagus (BE) is a premalignant condition caused by stomach acid or gastrointestinal reflux disease (GERD) mutating healthy cells in the lower esophagus into Barrett’s cells.  Approximately 90% of Esophageal Adenocarcinoma (EAC) patients do not receive a prior diagnosis of Barrett’s Esophagus (BE). BE affect’s more than 12 million American adults, and is associated with a 30-fold increased risk of developing EAC. This new treatment will provide an alternative to the Radiofrequency Ablation Technology (“RFA”) and cryoablation technologies currently in use for treatment of BE thereby reducing the number of episodes of treatment and providing unparalleled user control for adequate cell removal.

“We believe Symple Surgical has a superior solution to the problem in treating BE and EAC”, stated Dan Kasprzyk, President & CEO of Symple Surgical.  “We look forward to the future when clinicians are potentially able to take a more interventional and logical approach to treating Barrett’s Esophagus using our proprietary Grizzly™ Microwave Ablation device. Our development and commercialization pathways would be best served by seeking best-in-class strategic and financial partners to maximize the success of our technology.”

“The Objective Capital team is excited to be representing Symple Surgical, led by an experienced CEO Dan Kasprzyk, and their technology which has the potential to change the course of how Barrett’s Esophagus is treated,” said Jack J. Florio, Managing Director at Objective Capital Partners.  “There is a targeted list of both strategic and financial investors who we will be approaching to partner with Symple Surgical through the final development, approval and launch of this promising technology.”

About Symple Surgical, Inc.
Symple Surgical, Inc. (“SSI”), a Delaware corporation, founded in 2011, is an early stage medical device company developing device-based therapeutic microwave ablation technologies primarily for the treatment of Barrett’s Esophagus and esophageal adenocarcinoma. SSI’s interventional device and procedure seeks to create a safe and effective therapy for ablation of Barrett’s Esophagus and the subsequent elimination of “EAC”. Many of the approved therapies for treatment of “BE” require multiple episodes of treatment creating significant patient discomfort and unnecessary costs placed on our healthcare system. More information on SSI can be found at http://www.symplesurgical.com/.

About Objective Capital Partners
Objective Capital Partners is a leading investment banking firm serving the transaction needs of middle market and growth stage companies in five industry sectors of expertise: Technology, Consumer, Healthcare, Life Sciences, and Business Services. Headquartered in Southern California since 2006, the firm provides sell-side, buy-side, growth capital and valuation services. The executive team have collectively engaged in more than 500 successful transactions and bring a unique combination of investment banking, private equity, and business ownership experience that enables Objective Capital Partners to provide large enterprise caliber investment banking services to middle market companies. Additional information on Objective Capital Partners is available at www.objectivecp.com. 

 

Disclosure
Securities and investment banking services are offered through BA Securities, LLC Member FINRA, SIPC. Principals of Objective Capital are Registered Representatives of BA Securities. Objective Capital Partners and BA Securities are separate and unaffiliated entities. This news release is for informational purposes only and does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities. While the information provided herein is believed to be accurate and reliable, Objective Capital Partners and BA Securities, LLC make no representations or warranties, expressed or implied, as to the accuracy or completeness of such information. All information contained herein is preliminary, limited and subject to completion, correction or amendment. It should not be construed as investment, legal, or tax advice and may not be reproduced or distributed to any person.

Contact: Mandy F. Woods
Business Office Manager
Objective Capital Partners
Tel: 858-208-3442
mandy.woods@objectivecp.com

Daniel J. Kasprzyk
President & CEO
Symple Surgical
Tel: 928-699-2575
dank@symplesurgical.com

 

Our Services

Learn about our services and how we can help you sell your business successfully.

LEARN MORE

Contact Us

San Diego Office:
3636 Nobel Dr., Suite 160
San Diego, CA 92122

Los Angeles Office:
10100 Santa Monica Blvd., Suite 300
Los Angeles, CA 90067

Trever Acers
Managing Director
858.663.8662 telephone
trever.acers@objectivecp.com

Channing Hamlet
Managing Director
858.342.4939 telephone
channing.hamlet@objectivecp.com

David H. Crean, Ph.D.
Managing Director
858.461.9490 telephone
david.crean@objectivecp.com

Jack J. Florio
Managing Director
858.864.4339 telephone
jack.florio@objectivecp.com